Q2 EPS Forecast for NRx Pharmaceuticals Decreased by Analyst

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – HC Wainwright dropped their Q2 2026 EPS estimates for shares of NRx Pharmaceuticals in a report released on Thursday, May 28th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.05) per share for the quarter, down from their previous forecast of $0.02. HC Wainwright currently has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.23) EPS, Q1 2027 earnings at $0.00 EPS, Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at $0.21 EPS, FY2027 earnings at $0.67 EPS, FY2028 earnings at $2.49 EPS and FY2029 earnings at $4.51 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $19.43 million.

Several other analysts have also recently issued reports on the stock. Ascendiant Capital Markets upped their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, April 27th. BTIG Research restated a “buy” rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, March 24th. D. Boral Capital restated a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ NRXP opened at $4.42 on Monday. The firm’s 50-day moving average price is $2.78 and its 200-day moving average price is $2.37. The stock has a market capitalization of $160.14 million, a price-to-earnings ratio of -4.06 and a beta of 2.14. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $4.59.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ethos Financial Group LLC raised its position in NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares during the period. One Wealth Management Investment & Advisory Services LLC increased its position in shares of NRx Pharmaceuticals by 35.3% during the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after acquiring an additional 9,882 shares during the period. State Street Corp increased its position in shares of NRx Pharmaceuticals by 14.0% during the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after acquiring an additional 10,700 shares during the period. Sjbenen Advisory LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter worth approximately $41,000. Finally, Two Sigma Investments LP increased its position in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares during the period. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals News Summary

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to a loss of $0.23 from a prior forecast of a $0.13 profit, implying weaker short-term performance than previously expected. NRx Pharmaceuticals stock page
• Negative Sentiment: The firm also reduced near-term quarterly estimates, including Q2 2026 to $(0.05), Q3 2026 to $(0.06), and Q4 2026 to $(0.07), reinforcing concerns that losses may persist before growth improves. NRx Pharmaceuticals stock page
• Neutral Sentiment: Despite the cuts, HC Wainwright still expects a turnaround later on, with FY2027 EPS estimated at $0.67, FY2028 at $2.49, and FY2029 at $4.51, suggesting long-term upside remains in the analyst’s view. NRx Pharmaceuticals stock page

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.